8 Review of guidance

8 Review of guidance

8.1 The guidance on this technology will be considered for review by the Guidance Executive at the same time as Beta interferon and glatiramer acetate for the treatment of multiple sclerosis (NICE technology appraisal guidance 32) and Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis (NICE technology appraisal guidance 127). The Guidance Executive will decide whether the technology should be reviewed based on information gathered by NICE, and in consultation with consultees and commentators.

Andrew Dillon
Chief Executive
April 2012

  • National Institute for Health and Care Excellence (NICE)